🔎 Trials Near Me

Beranda › Adenokarsinoma Esofagus › South Dakota

Uji klinis Adenokarsinoma Esofagus di South Dakota

5 studi untuk Adenokarsinoma Esofagus mencari peserta di lokasi di South Dakota.

Kota di South Dakota

Teks studi resmi (Bahasa Inggris)

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

  • Rapid City Regional Hospital, Rapid City
  • Sanford Cancer Center Oncology Clinic, Sioux Falls
  • Sanford USD Medical Center - Sioux Falls, Sioux Falls
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT06203600

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

  • Avera Cancer Institute-Aberdeen, Aberdeen
  • Avera Cancer Institute - Mitchell, Mitchell
  • Avera Cancer Institute at Pierre, Pierre
  • dan 5 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05677490

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

  • Avera Cancer Institute, Sioux Falls
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT06324357

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

  • Research Site, Sioux Falls
  • Research Site, Yankton
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT07431281

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

  • Sanford Cancer Center, Sioux Falls
  • Sanford USD Medical Center, Sioux Falls
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT04389632

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.